

Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented During The American Academy Of Ophthalmology And American Academy Of Optometry Annual Meetings

October 07, 2019

BRIDGEWATER, N.J., Oct. 7, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced that 14 new scientific poster and clinical presentations involving the company's products, as well as data from the company's Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study, will be presented during the Annual Meetings of the American Academy of Ophthalmology and American Academy of Optometry in San Francisco (Oct. 12-15, 2019) and Orlando (Oct. 26-30, 2019), respectively.

"Bausch + Lomb is committed to supporting research designed to generate learnings about our products as well as broader insights for the eye health community – such as the unique ARMOR surveillance study," said Joe Gordon, U.S. president, Bausch + Lomb. "We invite eye care professionals attending both meetings to learn more about the results of these data to help inform them how they can better address the needs of their patients."

The full schedule of all scientific poster and clinical presentations that will include Bausch + Lomb products and the ARMOR study results is as follows:

American Academy of Ophthalmology

- Asbell, P et al. "Ten-Year Antibiotic Resistance Trends From Ocular Pathogens Collected in the ARMOR Surveillance Study." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
- DeCory H et al. "Antibiotic Resistance Among Intraocular Bacterial Pathogens Collected Over 10 Years in ARMOR." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
- Harasymowycz, P et al. "Effectiveness of Latanoprostene Bunod in Treating OAG and OHT: Network Meta-analysis." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m., also available as part of e-poster discussion session on Sunday, Oct. 12, 2019 from 12:15-12:45 e-poster Lounge, Station 3
- Liang, E et al. "Retinal Image Simulations of Aspheric IOLs With Nominal Tilt and Decentration." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
- Packer, M et al. "Optimizing Refractive Outcomes With a New Vergence-Based Algorithm for a Neutral Aspheric Monofocal Toric IOL." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m., also available as part of e-poster discussion session on Monday, Oct. 14, 2019 from 1:15-2:15 p.m., e-poster Lounge, Station 5
- Pizio, H et al. "Energy-Fluid Metrics Analysis of Patients Undergoing Vacuum-Based Phacoemulsification From Cloud-Based Database." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
- Rocha, K. et al. "Analysis of Static and Dynamic Factors Associated With Pseudoaccommodation in Monofocal IOLs." Friday, Oct. 11, 2019 at 7:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.
- Stephenson, Dee G et al. "Retinal Image Simulations of Aspheric Toric IOLs Under Conditions of Tilt and Decentration." Saturday, Oct. 12, 2019 at 9:00 a.m. to Tuesday, Oct. 15, 2019 at 1:00 p.m.

American Academy of Optometry

- Cavet M et al. "Loteprednol Etabonate (Submicron) 0.38% Gel for the Reduction of Inflammation and Pain following Cataract Surgery: Integrated Analysis of Three Phase 3 Studies." Poster #42, Exhibit Hall WD1, Orange County Convention Center, Thursday, Oct. 24, 2019 from 4:30 to 6:30 p.m. ET.
- DeCory H et al. "Real-world Persistence with Latanoprostene Bunod Ophthalmic Solution 0.024%: Analysis of Patient Longitudinal Data." W224 ABC, Orange County Convention Center, Friday, Oct. 25, 2019 at 2:00 p.m. ET.
- Rah M et al. "Identifying Opportunities for Contact Lens Wear Through Challenges Experienced by Presbyopic Astigmatic Patients Wearing Spectacles." Poster #50, Exhibit Hall WD1, Orange County Convention Center, Friday, Oct. 25, 2019 from 9 a.m. to 3 p.m. ET.
- Reindel WT et al. "Progressive Multifocal Contact Lenses for the Astigmatic Presbyope: A Comparison of Power Profiles Across Near, Intermediate and Distance Zones." Poster #51, Exhibit Hall WD1, Orange County Convention Center, Friday, Oct. 25, 2019 from 9 a.m. to 3 p.m. ET.
- Sanfilippo C et al. "Antibiotic Resistance Rates Among Bacterial Pathogens Collected from the Cornea in ARMOR." Poster #54, Exhibit Hall WD1, Orange County Convention Center, Thursday, Oct. 24, 2019 from 4:30 to 6:30 p.m. ET.
- Sanfilippo C et al. "Antibiotic Resistance Trends Among Ocular Pathogens in the United States: Ten-Year Results from the ARMOR Study." Poster #55, Exhibit Hall WD1, Orange County Convention Center, Thursday, Oct. 24, 2019 from 4:30 to 6:30 p.m. ET.

Important Safety Information for BESIVANCE® (besifloxacin ophthalmic suspension) 0.6%

Indication

BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: *Aerococcus viridans**, CDC coryneform group G,

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call **1-800-FDA-1088**.

Click [here](#) for full Prescribing Information for **LOTEMAX[®] SM**.

About Bausch + Lomb

Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies Inc., is a leading global eye health organization that is solely focused on helping people see better. Its core businesses include over-the-counter products, dietary supplements, eyecare products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

Forward-looking Statements

This news release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Bausch Health's most recent annual or quarterly report and detailed from time to time in Bausch Health's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates.

Any other product/brand names are trademarks of the respective owners.

© 2019 Bausch & Lomb Incorporated or its affiliates.

MTB.0448.USA.19

Bausch Health Investor:	Media Contact:
Arthur Shannon	Lainie Keller
arthur.shannon@bauschhealth.com	lainie.keller@bauschhealth.com
(514) 856-855	(908) 927-1198
(877) 281-6642 (toll free)	

BAUSCH Health

BAUSCH + LOMB

